Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,821 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply by Authors.
Trock BJ, Jing Y, Mabey B, Sangale Z, Lenz L, Haney N, Vidal I, Glavaris SA, Guner G, Ertunc O, Kulac I, Baena Del Valle JA, Jones T, Han M, Partin AW, Cohen T, Stone S, De Marzo AM. Trock BJ, et al. Among authors: stone s. J Urol. 2022 Dec;208(6):1192-1193. doi: 10.1097/JU.0000000000002922.02. Epub 2022 Dec 1. J Urol. 2022. PMID: 36349916 No abstract available.
Cell Cycle Progression Score, but Not Phosphatase and Tensin Homolog Loss, Is an Independent Prognostic Factor for Metastasis in Intermediate- and High-risk Prostate Cancer in Men Treated With and Without Salvage Radiotherapy.
Trock BJ, Jing Y, Mabey B, Sangale Z, Lenz L, Haney N, Vidal I, Glavaris SA, Guner G, Ertunc O, Kulac I, Baena Del Valle JA, Jones T, Han M, Partin AW, Cohen T, Stone S, De Marzo AM. Trock BJ, et al. Among authors: stone s. J Urol. 2022 Dec;208(6):1182-1193. doi: 10.1097/JU.0000000000002922. Epub 2022 Aug 25. J Urol. 2022. PMID: 36006048
Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.
Canter DJ, Reid J, Latsis M, Variano M, Halat S, Rajamani S, Gurtner KE, Sangale Z, Brawer M, Stone S, Bardot S. Canter DJ, et al. Among authors: stone s. Eur Urol. 2019 Mar;75(3):515-522. doi: 10.1016/j.eururo.2018.10.028. Epub 2018 Oct 31. Eur Urol. 2019. PMID: 30391079 Free article.
Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer.
Morris DS, Woods JS, Edwards B, Lenz L, Logan J, Flake DD, Mabey B, Bishoff JT, Cohen T, Stone S. Morris DS, et al. Among authors: stone s. Urol Oncol. 2021 Jun;39(6):366.e19-366.e28. doi: 10.1016/j.urolonc.2020.11.016. Epub 2020 Nov 27. Urol Oncol. 2021. PMID: 33257218 Free article.
Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy.
Léon P, Cancel-Tassin G, Drouin S, Audouin M, Varinot J, Comperat E, Cathelineau X, Rozet F, Vaessens C, Stone S, Reid J, Sangale Z, Korman P, Rouprêt M, Fromond-Hankard G, Cussenot O. Léon P, et al. Among authors: stone s. World J Urol. 2018 Sep;36(9):1495-1500. doi: 10.1007/s00345-018-2290-y. Epub 2018 Apr 20. World J Urol. 2018. PMID: 29679140
Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy.
Cuzick JM, Stone S, Lenz L, Flake DD, Rajamani S, Moller H, Berney DM, Cohen T, Scardino PT. Cuzick JM, et al. Among authors: stone s. Cancer Rep (Hoboken). 2022 Aug;5(8):e1535. doi: 10.1002/cnr2.1535. Epub 2021 Aug 22. Cancer Rep (Hoboken). 2022. PMID: 34423592 Free PMC article.
1,821 results